SG47948A1 - Compounds for the treatment of neurodegenerative disorders - Google Patents

Compounds for the treatment of neurodegenerative disorders

Info

Publication number: SG47948A1
Authority: SG; Singapore
Prior art keywords: treatment; neurodegenerative disorders; compounds; pyridineethanamine; alpha
Prior art date: 1992-04-03

Application number

SG1996005610A

Other languages

English (en)

Inventor

Michael Balestra

Ronald Conrad Griffith

Robert John Murray

Original Assignee

Astra Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-04-03

Filing date

1993-04-01

Publication date

1998-04-17

1992-04-03 Priority claimed from GB929207339A external-priority patent/GB9207339D0/en

1992-04-15 Priority claimed from GB929208290A external-priority patent/GB9208290D0/en

1993-04-01 Application filed by Astra Ab filed Critical Astra Ab

1998-04-17 Publication of SG47948A1 publication Critical patent/SG47948A1/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Neurology (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurosurgery (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)

SG1996005610A 1992-04-03 1993-04-01 Compounds for the treatment of neurodegenerative disorders SG47948A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB929207339A GB9207339D0 (en)	1992-04-03	1992-04-03	Pharmaceutical compound
GB929208290A GB9208290D0 (en)	1992-04-15	1992-04-15	Pharmaceutical compound having neuroprotective properties

Publications (1)

Publication Number	Publication Date
SG47948A1 true SG47948A1 (en)	1998-04-17

Family

ID=26300643

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG1996005610A SG47948A1 (en)	1992-04-03	1993-04-01	Compounds for the treatment of neurodegenerative disorders

Country Status (28)

Country	Link
EP (1)	EP0633879B1 (fr)
JP (2)	JP3120810B2 (fr)
KR (1)	KR100259567B1 (fr)
CN (1)	CN1044367C (fr)
AT (1)	ATE163925T1 (fr)
AU (2)	AU3897693A (fr)
CA (1)	CA2133427C (fr)
CZ (1)	CZ288519B6 (fr)
DE (1)	DE69317411T2 (fr)
DK (1)	DK0633879T3 (fr)
DZ (1)	DZ1677A1 (fr)
ES (1)	ES2115055T3 (fr)
FI (1)	FI105025B (fr)
HU (1)	HU211529A9 (fr)
IL (1)	IL105276A (fr)
MA (1)	MA22866A1 (fr)
MX (1)	MX9301935A (fr)
MY (1)	MY110149A (fr)
NO (1)	NO302170B1 (fr)
NZ (1)	NZ251384A (fr)
PL (1)	PL180014B1 (fr)
RU (1)	RU2128650C1 (fr)
SG (1)	SG47948A1 (fr)
SK (1)	SK281258B6 (fr)
TW (1)	TW282455B (fr)
UA (1)	UA29437C2 (fr)
WO (1)	WO1993020052A1 (fr)
ZA (1)	ZA932415B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9320273D0 (en)	1993-04-01	1993-11-17	Fisons Corp	Compound useful in therapy
EP0648489A1 (fr) *	1988-08-12	1995-04-19	Fisons Corporation	Arylalkylamides avec des propriétés neuroprotectives
ZA942140B (en) *	1993-04-01	1994-10-03	Fisons Corp	Salt of (S)-alpha-phenyl-2-pyridineethanamine useful in therapy
SE9901077D0 (sv) *	1999-03-23	1999-03-23	Astra Ab	Novel use
SE9901237D0 (sv) *	1999-04-06	1999-04-06	Astra Ab	Novel use
SE9901340D0 (sv)	1999-04-15	1999-04-15	Astra Pharma Prod	Novel process
NZ516782A (en) *	1999-07-28	2004-12-24	Ortho Mcneil Pharm Inc	Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders
WO2007017652A2 (fr) *	2005-08-10	2007-02-15	Astrazeneca Ab	Utilisation therapeutique
EA201190064A1 (ru)	2008-12-24	2012-02-28	Астразенека Аб	Соединения этанамина и их применение для лечения депрессии
JP2015501652A (ja) *	2011-12-14	2015-01-19	アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａＡｋｔｉｅｂｏｌａｇ	Ｇａｂｒ−ａ２診断
RS58991B1 (sr)	2013-11-05	2019-08-30	Astrazeneca Ab	Prolekovi nmda antagonista
WO2021262779A1 (fr) *	2020-06-23	2021-12-30	Biohaven Therapeutics Ltd.	Formulations topiques de (1s)-1-phényl-2-pyridin-2-yléthanamine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK689388A (da) *	1987-12-11	1989-06-12	Syntex Lab	Anvendelse af dihydropyridinderivater
EP0648489A1 (fr) *	1988-08-12	1995-04-19	Fisons Corporation	Arylalkylamides avec des propriétés neuroprotectives

1993
- 1993-04-01 EP EP93907975A patent/EP0633879B1/fr not_active Expired - Lifetime
- 1993-04-01 CA CA002133427A patent/CA2133427C/fr not_active Expired - Lifetime
- 1993-04-01 AT AT93907975T patent/ATE163925T1/de active
- 1993-04-01 SK SK1177-94A patent/SK281258B6/sk not_active IP Right Cessation
- 1993-04-01 AU AU38976/93A patent/AU3897693A/en not_active Abandoned
- 1993-04-01 JP JP05517251A patent/JP3120810B2/ja not_active Expired - Lifetime
- 1993-04-01 ES ES93907975T patent/ES2115055T3/es not_active Expired - Lifetime
- 1993-04-01 DE DE69317411T patent/DE69317411T2/de not_active Expired - Lifetime
- 1993-04-01 DK DK93907975T patent/DK0633879T3/da active
- 1993-04-01 PL PL93305404A patent/PL180014B1/pl unknown
- 1993-04-01 SG SG1996005610A patent/SG47948A1/en unknown
- 1993-04-01 RU RU94042465A patent/RU2128650C1/ru active
- 1993-04-01 NZ NZ251384A patent/NZ251384A/en not_active IP Right Cessation
- 1993-04-01 WO PCT/GB1993/000689 patent/WO1993020052A1/fr not_active Ceased
- 1993-04-01 UA UA94095853A patent/UA29437C2/uk unknown
- 1993-04-01 KR KR1019940703465A patent/KR100259567B1/ko not_active Expired - Lifetime
- 1993-04-01 CZ CZ19942409A patent/CZ288519B6/cs not_active IP Right Cessation
- 1993-04-02 IL IL105276A patent/IL105276A/xx not_active IP Right Cessation
- 1993-04-02 ZA ZA932415A patent/ZA932415B/xx unknown
- 1993-04-02 MY MYPI93000602A patent/MY110149A/en unknown
- 1993-04-02 MX MX9301935A patent/MX9301935A/es unknown
- 1993-04-02 MA MA23157A patent/MA22866A1/fr unknown
- 1993-04-03 DZ DZ930038A patent/DZ1677A1/fr active
- 1993-04-03 CN CN93104534A patent/CN1044367C/zh not_active Expired - Lifetime
- 1993-04-30 TW TW082103364A patent/TW282455B/zh not_active IP Right Cessation
1994
- 1994-09-30 FI FI944546A patent/FI105025B/fi not_active IP Right Cessation
- 1994-09-30 NO NO943645A patent/NO302170B1/no not_active IP Right Cessation
1995
- 1995-06-13 HU HU95P/P00192P patent/HU211529A9/hu unknown
1996
- 1996-12-18 AU AU75456/96A patent/AU705419B2/en not_active Expired
2000
- 2000-05-30 JP JP2000159319A patent/JP2000319259A/ja active Pending

Also Published As

Publication number	Publication date
DZ1677A1 (fr)	2002-02-17
IL105276A (en)	1997-06-10
AU705419B2 (en)	1999-05-20
KR100259567B1 (ko)	2000-07-01
SK117794A3 (en)	1995-05-10
ES2115055T3 (es)	1998-06-16
NO943645D0 (no)	1994-09-30
UA29437C2 (uk)	2000-11-15
MX9301935A (es)	1994-08-31
DE69317411T2 (de)	1998-07-30
CA2133427C (fr)	2003-06-10
CN1044367C (zh)	1999-07-28
JP3120810B2 (ja)	2000-12-25
NO302170B1 (no)	1998-02-02
AU3897693A (en)	1993-11-08
DK0633879T3 (da)	1998-09-28
EP0633879B1 (fr)	1998-03-11
JPH07505385A (ja)	1995-06-15
NZ251384A (en)	1996-10-28
FI944546L (fi)	1994-09-30
WO1993020052A1 (fr)	1993-10-14
CZ240994A3 (en)	1995-12-13
CZ288519B6 (cs)	2001-07-11
HU211529A9 (en)	1995-11-28
JP2000319259A (ja)	2000-11-21
RU2128650C1 (ru)	1999-04-10
MY110149A (en)	1998-02-28
RU94042465A (ru)	1996-07-20
CN1081669A (zh)	1994-02-09
CA2133427A1 (fr)	1993-10-14
IL105276A0 (en)	1993-08-18
ZA932415B (en)	1993-10-22
ATE163925T1 (de)	1998-03-15
PL180014B1 (pl)	2000-11-30
AU7545696A (en)	1997-02-13
HK1009331A1 (en)	1999-05-28
EP0633879A1 (fr)	1995-01-18
DE69317411D1 (de)	1998-04-16
FI105025B (fi)	2000-05-31
NO943645L (no)	1994-11-16
SK281258B6 (sk)	2001-01-18
FI944546A0 (fi)	1994-09-30
MA22866A1 (fr)	1993-12-31
TW282455B (fr)	1996-08-01

Publication	Publication Date	Title
AU610036B2 (en)	1991-05-09	Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis inflammation and as immunosuppressants
IL110204A0 (en)	1995-01-24	Novel indolene derivatives, processes for their preparation and their use for the treatment of cns disorders
WO1993000094A3 (fr)	1993-03-04	Utilisation de derives de tetrahydrobenzazepine pour le traitement de l'hypertension porte et de la migraine
EP0538898A3 (en)	1993-06-23	Cytotoxic bicyclo (7.3.1)-tridec-4-ene-2,6-diyne compounds and process for the preparation thereof
SG47948A1 (en)	1998-04-17	Compounds for the treatment of neurodegenerative disorders
GB9226832D0 (en)	1993-02-17	Pharmaceutical preparations for the treatment of psoriasis
EP0626162A3 (fr)	1995-03-01	Lit pour malades.
CA2135709A1 (fr)	1995-05-19	Derives de melatonine servant au traitement des troubles du sommeil
EP0592903A3 (fr)	1994-11-23	Utilisation du ancrod pour la préparation de médicaments pour le traitement de la restenosis.
CA2135710A1 (fr)	1995-05-19	Derives de melatonine servant au traitement des troubles de synchronisation
ZA933151B (en)	1993-12-06	Cycloheptimidazole derivatives, method of manufacturing the same and therapeutic agents containing these compounds.
HRP931016A2 (en)	1997-04-30	Thienothiazin derivatives, process for the preparation and application thereof
ZA935154B (en)	1994-02-08	Use of 1,2,5-oxadiazole-2-oxides for the treatment of erectile dysfunctions
GB9103278D0 (en)	1991-04-03	Drug for the treatment of dermatitis
ZA949347B (en)	1995-08-10	1,4,7,10-tetraazacyclododecane derivatives, their use, pharmaceutical agents containing these compounds and process for their production.
AU6581294A (en)	1994-11-21	Ethanolamine derivatives useful for the treatment of gastrointestinal disorders
EP0583136A3 (en)	1994-06-01	Piperidino-3,4-dihydrocarbostyryl compounds for the treatment of ischemic disorders
GR3036226T3 (en)	2001-10-31	6-methoxy-1h-benzotriazole-5-carboxamide derivatives, process for producing the same, and medicinal composition containing the same
IL89901A0 (en)	1989-12-15	Strobilurine derivatives
IL99236A0 (en)	1992-07-15	Pharmaceutical composition for the topical treatment of psoriasis
AU3084992A (en)	1993-07-19	1,4-dihydropyridines for use in the treatment of dermatosis
AU4825993A (en)	1994-04-12	New compounds for use in the treatment of cancer
GB2270313B (en)	1995-07-12	1,3,4-Benzotriazepin-5 (4H)-one derivatives and process for the preparation thereof
AU7183298A (en)	1998-07-30	Melatonin derivatives for use in treating desynchronization disorders
GR920100423A (el)	1994-06-30	Ανταγωνιστές 5-ΗΤ4 κινολιζιδινυλ εστέρος.